Fibronostics, a Singapore & New York-based company providing non-invasive, algorithmic diagnostics for NASH patients, secured $8 in Series A funding.
The round was led by AT Capital and Elev8.vc.
The financing will accelerate the commercialization of LIVERFASt in the U.S. and help the company expand its SaaS platform with new products targeting other disease states, including COVID-19, kidney and lung diseases.
Led by Roni Amiel, CEO, Fibronostics is a global diagnostics company, providing non-invasive, algorithmic diagnostics and insights to detect and manage organ lesions caused by metabolic diseases. The company leverages artificial intelligence to screen and measure the progression and prognosis of liver & kidney disease as well as other chronic conditions.
Fibronostics is advancing LIVERFASt, a non-invasive patented test that works with a simple blood draw. Using a combination of AI technology and broadly available biomarkers, the test enables precise staging of organ lesions to diagnose liver disease. A cloud platform offers integration with healthcare providers to deliver the right treatment at the right time. LIVERFASt is commercialized on in North America, Asia, Europe and LATAM, screening more than 70K patients.